BlueCross BlueShield of Florida began covering the test on March 15, and Health Care Services Corporation will begin coverage in June.
Norgen Biotek's sample prep products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.
The company said it will use the funds to continue developing new companion diagnostics and expand commercialization of its VeriStrat and GeneStrat products
The company last year launched a PCR-based assay for identifying mutations in lung cancer patients and plans to release an NGS-based test later this year.
In a study looking at a total of 149 subjects with advanced unresectable melanoma, the test proved useful for distinguishing between good and poor responders.
The Colorado-based cancer diagnostics firm said in an SEC document that it seeks to raise up to $20 million.
The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
The $11 million is in addition to $27 million that the company raised previously in a Series E financing, bringing the total proceeds to $38 million.
The company has received similar coverage decisions from other payors in recent months.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.